Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Urogenital Neoplasms × Tadalafil × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5 Prostatic Neoplasms 3 Head and Neck Neoplasms 3 Neoplasms 2 Erectile Dysfunction 2 Carcinoma 2 Adenocarcinoma 2 Urogenital Neoplasms 1 Pyridoxine-dependent epilepsy 1 Peripheral Nervous System Diseases 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Neurotoxicity Syndromes 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Mouth Neoplasms 1 Glioblastoma 1 Gastric Adenocarcinoma 1 Esophageal Neoplasms 1 Astrocytoma 1 Abdominal Cancer 1

Interventions

padeliporfin 4 vedolizumab 2 atezolizumab 2 anlotinib 2 Therapeutics 2 Surveys and Questionnaires 2 Riluzole 2 Radiotherapy 2 Nivolumab 2 LDP-02 2 Ipilimumab 2 Infliximab 2 Immunoglobulin G 2 Genetic Testing 2 Fecal Microbiota Transplantation 2 Disulfides 2 CT-P13 2 tislelizumab 1 prednylidene 1 pembrolizumab 1 palladium-bacteriopheophorbide 1 olaparib 1 ixabepilone 1 ferumoxtran-10 1 enfortumab vedotin 1 deltacortene 1 darolutamide 1 Technetium Tc 99m Medronate 1 Taste 1 Tadalafil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06717711 2024-12-05

RCT_LiESWT

Regina Elena Cancer Institute

Phase 3 Recruiting

Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡